<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03437421</url>
  </required_header>
  <id_info>
    <org_study_id>UAPV-022018-SFC</org_study_id>
    <nct_id>NCT03437421</nct_id>
  </id_info>
  <brief_title>Myocardial Function and Vitamin D Supplementation in Diabetes.</brief_title>
  <acronym>VitaDD</acronym>
  <official_title>Effect of Vitamin D Supplementation on Myocardial Regional Function by Dobutamine Stress Echocardiography in Diabetic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Avignon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Avignon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D deficiency is recognized as a cardiovascular risk factor. Diabetic patients are of&#xD;
      major risk for cardiovascular diseases and typically present with Vitamin D deficiencies.&#xD;
      Myocardial function is altered in both type I and II diabetic patients but no data is today&#xD;
      available on the effect of Vitamin D supplementation.&#xD;
&#xD;
      The aim of the study will be to investigate myocardial function (by deformation imaging&#xD;
      techniques) at rest and during low-dose dobutamine stress echocardiography in both type I and&#xD;
      II diabetic patients. Within each diabetic population, myocardial function will be compared&#xD;
      at baseline between the vitamin D deficient and non-deficient individuals. Furthermore, the&#xD;
      investigators will study the effect of a 3 month supplementation in those with deficiencies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Vitamin D exerts a principal role in homeostasis of calcium and phosphorus. However, recent&#xD;
      studies indicated also its important function in cell differentiation, proliferation and&#xD;
      growth as well as regulation of the immune system.&#xD;
&#xD;
      Vitamin Deficiency is today recognized as a risk factor for cardiovascular disease (CVD).&#xD;
      Diabetic patients are of major risk for CVD. They typically present with Vitamin D&#xD;
      deficiencies. Experimental studies have established as a result of Vitamin D deficiency&#xD;
      alterations in intrinsic cardiac contractile and relaxation properties, hypertrophy and&#xD;
      fibrosis. Regional myocardial function is altered in both type I and II diabetic patients. In&#xD;
      type II diabetic individuals, myocardial dysfunction is furthermore exacerbated in those with&#xD;
      Vitamin D deficiency compared to those with normal levels. In patients free from CV risk and&#xD;
      deficient in Vitamin D, regional myocardial function improved after Vitamin D&#xD;
      supplementation. To the best of our knowledge, no scientific study is today available on the&#xD;
      effect of Vitamin D supplementation on regional myocardial function in diabetic patients&#xD;
      deficient in vitamin D.&#xD;
&#xD;
      Objectives and Methodology:&#xD;
&#xD;
        -  To compare regional myocardial linear deformation and torsion, at rest and in response&#xD;
           to a DB stress in diabetic patients deficient and non-deficient in Vitamin D.&#xD;
&#xD;
        -  To evaluate the impact of vitamin D supplementation in those with vitamin D deficiency.&#xD;
&#xD;
      All the diabetic patients will benefit from a clinical (medical history, drug therapy, ECG,&#xD;
      blood pressure, ...), anthropometric (abdominal obesity indices) and biological (carbohydrate&#xD;
      and lipid balance, markers of inflammation and heart failure, vitamin D glucose and insulin&#xD;
      status) evaluation. In addition, conventional echocardiography (remodelling and global&#xD;
      diastolic and systolic function) complemented by a functional analysis by tissue Doppler&#xD;
      imaging will be performed. Furthermore, 2D cine loops will be recorded in the apical 4, 3 and&#xD;
      2- chamber views for the assessment of regional myocardial longitudinal deformations as well&#xD;
      as in the parasternal short axis (base, mid and apex) for the evaluation of circumferential&#xD;
      deformations and basal and apical rotation and torsion, at rest and under low dose dobutamine&#xD;
      (110 and 120 bpm).&#xD;
&#xD;
      Vitamin D supplementation:&#xD;
&#xD;
      Patients with vitamin D deficiency will be investigated before and after a 3 month&#xD;
      cholecalciferol supplementation.&#xD;
&#xD;
      For this purpose 25-OH-D3 with be evaluated at baseline.&#xD;
&#xD;
        -  Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100&#xD;
           000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge,&#xD;
           France) followed thereafter for the last 2 months by one daily dose (5 drops orally = 1&#xD;
           000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).&#xD;
&#xD;
        -  Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0&#xD;
           + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™ Laboratoires Crinex,&#xD;
           Montrouge, France) followed thereafter for the last month by one daily dose (5 drops&#xD;
           orally =1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).&#xD;
&#xD;
        -  Patients with : 25-OH-D3 &lt;10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 +&#xD;
           100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™&#xD;
           Laboratoires Crinex, Montrouge, France) followed thereafter for the last month by one&#xD;
           daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ , DB Pharma, La&#xD;
           Varenne-Saint-Hilaire, France).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Type I and II diabetic patients will be investigated. Within each diabetic population, vitamin D deficient and non-deficient individuals will be compared at baseline. Then, within each diabetic population, those with vitamin D deficiency at baseline will be compared before and after a 3 month vitamin D supplementation.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Single-masked study. Clinicians and researchers in charge of main outcomes (eg cardiac remodelling and global function, regional myocardial function) measurements will not be aware of group allocation (eg vitamin D deficient and non-deficient sub-groups) and time study (eg baseline or post vitamin D supplementation).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in longitudinal strain</measure>
    <time_frame>Before and after 3 month of Vitamin D supplementation</time_frame>
    <description>Index of myocardial function measured using deformation imaging technique by echocardiography, at rest and under dobutamine stress.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes Complications</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Vitamin D Supplementation</condition>
  <condition>Myocardial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Type II diabetic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type I diabetic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 (cholecalciferol)</intervention_name>
    <description>Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100 000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge, France) followed for the last 2 months by one daily dose (5 drops orally = 1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).&#xD;
Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0 + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ ).&#xD;
Patients with : 25-OH-D3 &lt;10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 + 100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™).</description>
    <arm_group_label>Type I diabetic patients</arm_group_label>
    <arm_group_label>Type II diabetic patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Male and female 40-65 years old, asymptomatic and free from epicardial coronary artery&#xD;
        disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  body mass index &gt; 35 kg / m2, defining severe obesity,&#xD;
&#xD;
          -  Under insulin therapy (for Type II only)&#xD;
&#xD;
          -  Poorly controlled hypertension (&gt; 140/95)&#xD;
&#xD;
          -  LV ejection fraction (LVEF) &lt; 55%&#xD;
&#xD;
          -  Peripheral vascular disease (&gt; stage II of Leriche)&#xD;
&#xD;
          -  Heart disease or known coronary artery disease,&#xD;
&#xD;
          -  Known and poorly compensated thyroid dysfunction,&#xD;
&#xD;
          -  Nocturnal apnea syndrome,&#xD;
&#xD;
          -  Inability to give written informed consent,&#xD;
&#xD;
          -  Chronic diseases,&#xD;
&#xD;
          -  moderate to severe left ventricular hypertrophy :&gt; 109 g / m2 in women and&gt; 132 g / m2&#xD;
             in men and parietal thickness &gt; 13mm.&#xD;
&#xD;
          -  poor glycemic control (HbA1c &gt; 9%)&#xD;
&#xD;
          -  poor echogenicity&#xD;
&#xD;
          -  severe autonomic or peripheral neuropathy,&#xD;
&#xD;
          -  Severe diabetic retinopathy,&#xD;
&#xD;
          -  Advanced Diabetic nephropathy (defined by documented proteinuria and/or renal&#xD;
             failure).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <state>Paca</state>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Falah Aboukhoudir, MD</last_name>
      <phone>+33622085526</phone>
      <email>faboukhoudir@ch-avignon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial function</keyword>
  <keyword>vitamin D</keyword>
  <keyword>stress echocardiography</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

